PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company, has announced that it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, before the market opens. The company, which focuses on developing innovative cancer immunotherapies and infectious disease vaccines, will also provide a business update along with the financial report.
Investors and interested parties can access the press release containing the financial results and business update in the Investor Relations section of PDS Biotech's official website at www.pdsbiotech.com. This announcement signals the company's commitment to transparency and regular communication with its shareholders and the broader investment community.
PDS Biotechnology (Nasdaq: PDSB), un'azienda di immunoterapia in fase avanzata, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il martedì 13 agosto 2024, prima dell'apertura del mercato. L'azienda, che si concentra nello sviluppo di innovative immunoterapie contro il cancro e vaccini per le malattie infettive, fornirà anche un aggiornamento aziendale insieme al report finanziario.
Investitori e parti interessate possono accedere al comunicato stampa contenente i risultati finanziari e l'aggiornamento aziendale nella sezione Relazioni con gli Investitori del sito ufficiale di PDS Biotech all'indirizzo www.pdsbiotech.com. Questo annuncio segnala l'impegno dell'azienda verso la trasparenza e una comunicazione regolare con i suoi azionisti e la più ampia comunità degli investimenti.
PDS Biotechnology (Nasdaq: PDSB), una empresa de inmunoterapia en etapa avanzada, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 13 de agosto de 2024, antes de la apertura del mercado. La empresa, que se enfoca en desarrollar innovadoras inmunoterapias contra el cáncer y vacunas para enfermedades infecciosas, también proporcionará una actualización sobre el negocio junto con el informe financiero.
Los inversores y partes interesadas pueden acceder al comunicado de prensa que contiene los resultados financieros y la actualización empresarial en la sección de Relaciones con Inversores del sitio web oficial de PDS Biotech en www.pdsbiotech.com. Este anuncio señala el compromiso de la empresa con la transparencia y la comunicación regular con sus accionistas y la comunidad más amplia de inversores.
PDS Biotechnology (Nasdaq: PDSB), 후기 단계 면역 요법 회사가 2024년 2분기 재무 결과를 2024년 8월 13일 화요일, 시장 개장 전에 발표할 것이라고 발표했습니다. 이 회사는 혁신적인 암 면역 요법 및 감염병 백신 개발에 주력하고 있으며, 재무 보고서와 함께 사업 업데이트도 제공할 것입니다.
투자자와 이해관계자는 PDS Biotech의 공식 웹사이트 www.pdsbiotech.com의 투자자 관계 섹션에서 재무 결과 및 사업 업데이트가 포함된 보도 자료를 접할 수 있습니다. 이 발표는 회사가 주주 및 더 넓은 투자 커뮤니티와의 투명성과 정기적인 소통에 대한 의지를 나타냅니다.
PDS Biotechnology (Nasdaq: PDSB), une société d'immunothérapie en phase avancée, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 13 août 2024, avant l'ouverture du marché. L'entreprise, qui se concentre sur le développement d'immunothérapies innovantes contre le cancer et de vaccins contre les maladies infectieuses, fournira également une mise à jour des affaires en même temps que le rapport financier.
Les investisseurs et les parties intéressées peuvent accéder au communiqué de presse contenant les résultats financiers et la mise à jour des affaires dans la section Relations Investisseurs du site officiel de PDS Biotech à l'adresse www.pdsbiotech.com. Cette annonce témoigne de l'engagement de l'entreprise envers la transparence et la communication régulière avec ses actionnaires et la communauté d'investissement au sens large.
PDS Biotechnology (Nasdaq: PDSB), ein Unternehmen für Immuntherapien in fortgeschrittener Phase, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Dienstag, den 13. August 2024, vor Markteröffnung veröffentlichen wird. Das Unternehmen, das sich auf die Entwicklung innovativer Krebsimmuntherapien und Impfstoffe gegen Infektionskrankheiten konzentriert, wird auch ein geschäftliches Update zusammen mit dem Finanzbericht bereitstellen.
Investoren und interessierte Parteien können die Pressemitteilung mit den Finanzergebnissen und dem geschäftlichen Update im Bereich Investor Relations der offiziellen Website von PDS Biotech unter www.pdsbiotech.com einsehen. Diese Ankündigung signalisiert das Engagement des Unternehmens für Transparenz und regelmäßige Kommunikation mit seinen Aktionären und der breiteren Investmentgemeinschaft.
- Timely reporting of quarterly financial results
- Commitment to investor communication and transparency
- None.
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company’s website at www.pdsbiotech.com.
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.
For more information, please visit www.pdsbiotech.com.
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Gina Mangiaracina
6 Degrees
Phone +1 (917) 797-7904
Email: gmangiaracina@6degreespr.com
FAQ
When will PDS Biotech (PDSB) release its Q2 2024 financial results?
Where can investors find PDS Biotech's (PDSB) Q2 2024 financial results?
What is PDS Biotech's (PDSB) primary focus as a company?
Will PDS Biotech (PDSB) provide a business update with its Q2 2024 results?
